National Registry of Diseases Office, Health Promotion Board, Singapore.
National University Heart Centre, National University Hospital, Singapore.
Am J Cardiol. 2019 Jun 15;123(12):1935-1940. doi: 10.1016/j.amjcard.2019.03.021. Epub 2019 Mar 19.
It is unclear whether universal access to primary percutaneous coronary intervention (pPCI) may reduce sex differences in 1-year rehospitalization for heart failure (HF) and myocardial infarction (MI) after ST-elevation myocardial infarction (STEMI). We studied 7,597 consecutive STEMI patients (13.8% women, n = 1,045) who underwent pPCI from January 2007 to December 2013. Cox regression models adjusted for competing risk from death were used to assess sex differences in rehospitalization for HF and MI within 1 year from discharge. Compared with men, women were older (median age 67.6 vs 56.0 years, p < 0.001) with higher prevalence of co-morbidities and multivessel disease. Women had longer median door-to-balloon time (76 vs 66 minutes, p < 0.001) and were less likely to receive drug-eluting stents (19.5% vs 24.1%, p = 0.001). Of the medications prescribed at discharge, fewer women received aspirin (95.8% vs 97.6%, p = 0.002) and P2Y antagonists (97.6% vs 98.5%, p = 0.039), but there were no significant sex differences in other discharge medications. After adjusting for differences in baseline characteristics and treatment, sex differences in risk of rehospitalization for HF attenuated (hazard ratio [HR] 1.05, 95% confidence interval [CI] 0.79 to 1.40), but persisted for MI (HR 1.68, 95% CI 1.22 to 2.33), with greater disparity in patients aged ≥60 years (HR 1.83, 95% CI 1.18 to 2.85) than those aged <60 years (HR 1.45, 95% CI 0.84 to 2.50). In conclusion, in a setting of universal access to pPCI, the adjusted risk of 1-year rehospitalization for HF was similar in both sexes, but women had significantly higher adjusted risk of 1-year rehospitalization for MI, especially older women.
目前尚不清楚普及直接经皮冠状动脉介入治疗(pPCI)是否可以缩小 ST 段抬高型心肌梗死(STEMI)后心力衰竭(HF)和心肌梗死(MI) 1 年内再住院治疗的性别差异。我们研究了 7597 例连续 STEMI 患者(13.8%为女性,n=1045),这些患者在 2007 年 1 月至 2013 年 12 月期间接受了 pPCI。采用竞争风险 Cox 回归模型评估出院后 1 年内因 HF 和 MI 再住院的性别差异。与男性相比,女性年龄较大(中位数年龄 67.6 岁 vs 56.0 岁,p<0.001),合并症和多血管疾病的患病率较高。女性的中位门球时间较长(76 分钟 vs 66 分钟,p<0.001),接受药物洗脱支架的可能性较低(19.5% vs 24.1%,p=0.001)。在出院时开具的药物中,接受阿司匹林治疗的女性比例较低(95.8% vs 97.6%,p=0.002)和 P2Y 拮抗剂(97.6% vs 98.5%,p=0.039),但在其他出院药物方面,性别间无显著差异。在校正基线特征和治疗差异后,HF 再住院风险的性别差异减弱(风险比 [HR] 1.05,95%置信区间 [CI] 0.79 至 1.40),但 MI 仍存在(HR 1.68,95% CI 1.22 至 2.33),年龄≥60 岁的患者(HR 1.83,95% CI 1.18 至 2.85)比年龄<60 岁的患者(HR 1.45,95% CI 0.84 至 2.50)差异更大。总之,在普及直接经皮冠状动脉介入治疗的情况下,两性之间 1 年 HF 再住院的调整风险相似,但女性 1 年 MI 再住院的调整风险明显更高,尤其是老年女性。